Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality9/10

Afya 2Q26 results confirm growth, cash generation and 2026 guidance

Aug 13, 2026, 6:10 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The company delivered organic revenue growth, solid cash generation, and reaffirmed 2026 targets, all of which historically support share price upside. Positive near-term catalysts include Moody's rating confirmation and strong FCFE payout; risks include margin compression and regulatory/Acquisition execution risk (ENAMED, FUNIC).

AI summary

What happened, with direct paths to the underlying reporting

Afya reported Q2 2026 revenue of R$972.1m, up 5.7% YoY, with Adjusted EBITDA of R$406.5m and net income of R$201.3m. 1H26 cash from operations reached R$805.6m on a solid balance sheet of R$1,006.5m cash, while management reaffirmed 2026 targets and highlighted shareholder returns of R$447.9m via dividends and buybacks. The firm also notes a robust ecosystem with nearly 295k users, signaling continued enrollment and cross-segment growth ahead.

2Q26 revenue 972.1m R$; YoY +5.7% (5.4% organic).
Adjusted EBITDA 406.5m R$; margin 41.8% (down 180bps).
1H26 revenue 1,984.8m R$; Free Cash Flow to Equity yield 11%.
Guidance reaffirmed: 2026 revenue 3.95–4.10b; EBITDA 1.70–1.80b; CAPEX 340–380m.
Moody's AAA.br reaffirmation; robust liquidity; ecosystem users ~295k.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Afya 2Q26 results confirm growth, cash generation and 2026 guidance

Afya to Expand Medical Education Reach With FUNIC Acquisition

AFYA Welcomes 300 Operational Medical School Seats in Salvador